Fidelity Management and Research Company appeared to be the VC, which was created in 1946. The fund was located in North America if to be more exact in United States. The leading representative office of defined VC is situated in the Boston.
Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The top amount of exits for fund were in 2018. Opposing the other organizations, this Fidelity Management and Research Company works on 12 percentage points more the average amount of lead investments. The typical startup value when the investment from Fidelity Management and Research Company is more than 1 billion dollars. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. The common things for fund are deals in the range of more than 100 millions dollars.
The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Fidelity Management and Research Company, startups are often financed by Atlas Venture, Venrock, The Column Group. The meaningful sponsors for the fund in investment in the same round are Invus, Wellington Management, Redmile Group. In the next rounds fund is usually obtained by ARCH Venture Partners, EcoR1 Capital, T. Rowe Price.
Among the most popular portfolio startups of the fund, we may highlight Lyft, Moderna Therapeutics, Magic Leap. The fund has no exact preference in some founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Pharmaceutical, Medical Device. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
The overall number of key employees were 2.
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Evozyne | $81M | 27 Sep 2023 | Chicago, Illinois, United States | ||
Generate Biomedicines | $273M | 15 Sep 2023 | Pennsylvania, United States | ||
Rapport Therapeutics | $150M | 23 Aug 2023 | Boston, Massachusetts, United States | ||
Genesis Therapeutics | $200M | 21 Aug 2023 | South San Francisco, California, United States | ||
GenePlanet | $23M | 13 Jul 2023 | Ljubljana, Ljubljana Urban Commune, Slovenia | ||
Lightmatter | $154M | 31 May 2023 | Boston, Massachusetts, United States | ||
Asimov | $175M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Apogee Therapeutics | $149M | 07 Dec 2022 | San Francisco, California, United States |
– VEG announced a $100m financing round co-led by D1 Capital Partners and Fidelity Management & Research Company, and supported by Durable Capital Partners.
– This third round of financing will bring total equity raised to an estimated $150m since inception and positions VEG to continue to invest in its people by providing the best support system and work culture within the veterinary field.
– Checkr is a San Francisco CA-based HR technology company.
– Company raised $250m in Series E funding, valuing it at $4.6b.
– The round was led by Durable Capital, Fidelity Management & Research Company LLC and Franklin Templeton with participation from BOND Capital, Khosla Ventures, IVP, T. Rowe Price, Coatue, Accel and Y Combinator.
– The new investment will be used to expand operations and business reach.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
AgomAb Therapeutics | $111M | 11 Oct 2023 | Ghent, East Flanders, Belgium | ||
Evozyne | $81M | 27 Sep 2023 | Chicago, Illinois, United States | ||
Generate Biomedicines | $273M | 15 Sep 2023 | Pennsylvania, United States | ||
Rapport Therapeutics | $150M | 23 Aug 2023 | Boston, Massachusetts, United States | ||
Genesis Therapeutics | $200M | 21 Aug 2023 | South San Francisco, California, United States | ||
GenePlanet | $23M | 13 Jul 2023 | Ljubljana, Ljubljana Urban Commune, Slovenia | ||
Lightmatter | $154M | 31 May 2023 | Boston, Massachusetts, United States | ||
Asimov | $175M | 05 Jan 2023 | Boston, Massachusetts, United States | ||
Apogee Therapeutics | $149M | 07 Dec 2022 | San Francisco, California, United States |
